Inhibition and diagnostics of emerging tetracycline resistance enzymes

US10273468B2 · kind B2 · utility

Assignee

• Washington University · US

Inventors

• Niraj H. Tolia · Chesterfield, US
• Gautam Dantas · Brookline, US
• Timothy Wencewicz · Chesterfield, US
• Jooyoung PARK · Chesterfield, US
• Andrew John GASPARRINI · Chesterfield, US
• Kevin Forsberg · Chesterfield, US
• Joseph Vogel · Chesterfield, US
• Margaret R. Reck · Chesterfield, US
• Chanez Tiffany Symister · Chesterfield, US
• Jana L. Markley · Chesterfield, US

Key dates

• Filing date: Jun 26, 2017
• Grant date: Apr 30, 2019
• Expiry date: Jun 26, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides compositions and methods for treating bacterial infections in a subject. The methods comprise administering a compound that binds a FAD-dependent flavoenzyme and a tetracycline, analog, derivative, or pharmaceutically acceptable salt thereof.